
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
IPI-145 and ABT-199 for Lymphoid Malignancies
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.
Learn more about inhibiting BCL-2 > >
Articles in this issue
almost 12 years ago
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AMLalmost 12 years ago
In the Pipeline: Potential New Treatments for AMLalmost 12 years ago
Epidemiology in B-Cell Malignanciesalmost 12 years ago
Pathogenesis of Follicular Lymphomaalmost 12 years ago
Resistance to Ibrutinibalmost 12 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLalmost 12 years ago
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL































